NASDAQ:CGEM

Cullinan Oncology Competitors

$32.30
-1.88 (-5.50 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.63
Now: $32.30
$34.80
50-Day Range
$34.18
MA: $43.17
$53.42
52-Week Range
$27.01
Now: $32.30
$59.85
Volume74,100 shs
Average Volume293,677 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cullinan Oncology (NASDAQ:CGEM) Vs. ABCM, SEER, NUVB, IBRX, BCAB, and IMCR

Should you be buying CGEM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Cullinan Oncology, including Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), and Immunocore (IMCR).

Abcam (NASDAQ:ABCM) and Cullinan Oncology (NASDAQ:CGEM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abcam and Cullinan Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Cullinan Oncology01302.75

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 10.61%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Cullinan Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Oncology is more favorable than Abcam.

Valuation and Earnings

This table compares Abcam and Cullinan Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares Abcam and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Cullinan Oncology beats Abcam on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Cullinan Oncology (NASDAQ:CGEM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and Cullinan Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Cullinan Oncology01302.75

Seer presently has a consensus price target of $68.00, suggesting a potential upside of 30.79%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Cullinan Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Oncology is more favorable than Seer.

Valuation and Earnings

This table compares Seer and Cullinan Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares Seer and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Cullinan Oncology beats Seer on 3 of the 3 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Cullinan Oncology and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
Nuvation Bio00603.00

Cullinan Oncology presently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Cullinan Oncology.

Valuation & Earnings

This table compares Cullinan Oncology and Nuvation Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Profitability

This table compares Cullinan Oncology and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Nuvation BioN/AN/AN/A

Summary

Nuvation Bio beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
ImmunityBio00103.00

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 48.19%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than ImmunityBio.

Valuation and Earnings

This table compares Cullinan Oncology and ImmunityBio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Cullinan Oncology and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
ImmunityBioN/AN/AN/A

Summary

Cullinan Oncology beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and BioAtla, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
BioAtla00403.00

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. BioAtla has a consensus target price of $58.00, suggesting a potential upside of 22.49%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than BioAtla.

Valuation and Earnings

This table compares Cullinan Oncology and BioAtla's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares Cullinan Oncology and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Cullinan Oncology and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
ImmunocoreN/AN/AN/A

Valuation and Earnings

This table compares Cullinan Oncology and Immunocore's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and Immunocore, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
Immunocore01202.67

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. Immunocore has a consensus target price of $54.3333, suggesting a potential upside of 53.18%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Cullinan Oncology.

Summary

Cullinan Oncology beats Immunocore on 2 of the 3 factors compared between the two stocks.


Cullinan Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abcam logo
ABCM
Abcam
1.5$19.89-1.0%$4.51 billionN/A0.00
SEER
Seer
1.2$51.99-3.2%$3.17 billionN/A0.00
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00-0.2%$2.18 billionN/A0.00High Trading Volume
IBRX
ImmunityBio
1.7$16.87-10.8%$1.84 billionN/A0.00Analyst Revision
BioAtla logo
BCAB
BioAtla
1.5$47.35-0.7%$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47-2.3%$1.53 billionN/A0.00
EWTX
Cricut
0.3$29.54-1.6%$1.41 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$31.55-0.5%$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07-5.4%$1.33 billionN/A0.00Analyst Revision
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12-9.2%$1.29 billionN/A0.00
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02-5.2%$1.19 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.69-7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00-3.5%$948.89 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01-11.1%$948.02 millionN/A0.00Insider Selling
Analyst Revision
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32-0.1%$901.71 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50-6.1%$885.10 millionN/A0.00
PHAR
Pharming Group
0.0$13.26-1.1%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Revision
FNCH
Finch Therapeutics Group
0.3$17.18-1.9%$809.95 millionN/A0.00News Coverage
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22-6.1%$568.45 millionN/A0.00Analyst Revision
SGTX
Sigilon Therapeutics
1.4$17.76-1.7%$559.32 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.44-2.2%$557.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93-2.9%$475.62 millionN/A0.00Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48-1.4%$456.41 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13-4.7%$432.21 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.85-2.4%$406.23 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93-2.3%$398.37 millionN/A0.00
PRTG
Portage Biotech
0.0$29.23-2.0%$353.19 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83-1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07-6.2%$300.24 millionN/A-2.79
LBPH
Longboard Pharmaceuticals
1.9$16.00-0.0%$270.67 millionN/A0.00Analyst Revision
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54-0.8%$262.47 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$12.28-5.1%$234.78 millionN/A0.00Gap Up
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54-0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98-0.1%$158.41 millionN/A0.00Gap Down
VINC
Vincerx Pharma
1.0$19.06-0.9%$156.39 millionN/A0.00
LGVN
Longeveron
0.3$6.81-0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09-9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
Gap Down
UPC
Universe Pharmaceuticals
0.0$4.64-3.2%$100.92 millionN/A0.00Gap Up
VRDN
Viridian Therapeutics
1.7$15.66-6.7%$61.20 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62-0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17-2.3%$51.40 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87-1.0%$45.59 millionN/A0.00News Coverage
Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66-1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86-23.5%$24.03 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$45.90-19.8%$21.30 millionN/A0.00High Trading Volume
Gap Up
VYNT
Vyant Bio
0.0$4.02-4.0%$16.42 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$5.21-15.9%$4.02 millionN/A0.00High Trading Volume
Gap Down
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.